{
  "figure_1": "Top 21 countries by number of COVID-19 candidate\nvaccines in the development pipelines.",
  "figure_2": "Distribution of COVID-19\nvaccine candidates among different vaccine platforms and their development\nstages.",
  "figure_3": "Distribution of COVID-19 vaccine candidates\nin clinical trials among top seven countries regarding the trial stages\nand vaccine platforms.",
  "figure_4": "Vaccine platforms and their ways of producing immunogen in cells.\n(A) Inactivated vaccine results in a broader spectrum of antigens\nwhen it is taken up and broken down by cells. (B) Protein-based vaccine\nproduces a more focused response to a targeted antigen when it is\ntaken up and processed into multiple epitopes by cells. (C) Viral\nvector vaccine delivers antigen-encoding DNA to cells and enhances\nthe inflammatory response and immunity. (D) Nucleic acid vaccine enters\ncells and serves as the transcriptional/translational template for\nprotein antigen synthesis.",
  "figure_5": "Schematic illustration\nof an mRNA molecule with the structural elements.",
  "figure_6": "Chemical structures of uridine, pseudouridine, and N1-methyl-pseudouridine.",
  "figure_7": "Suggested structures of lipid nanoparticle\nvaccine carriers: mRNA organized in inverse lipid micelles inside\nthe nanoparticle97−99 (A); mRNA intercalated between the lipid bilayers100 (B).",
  "figure_8": "COVID-19 vaccine-related\njournal article publications classified according to country (A) and\norganization (B); values are presented as number per thousand (‰).\nThe increase in color intensity reflects the increase in the number\nof publications.",
  "figure_9": "Distribution\nof COVID-19 vaccine-related journal publications in different research\nareas.",
  "figure_10": "Distribution of COVID-19-related\njournal publications among vaccine platforms.",
  "figure_11": "COVID-19 cross-protection by other vaccines. Numbers of documents\nare next to the vaccine names. In the inset pie-charts for BCG, influenza,\nand MMR, “Yes” indicates documents suggesting cross-protection,\n“No” indicates documents suggesting there is no cross-protection;\n“?” indicates documents which are inconclusive. “Other\nvaccines” include encephalitis, hepatitis, Newcastle disease,\nrotavirus, polio, and other routine childhood vaccines.",
  "figure_12": "Structure\nof the chemically modified cyclic dinucleotide adjuvant from patent\napplication CN111956797A. Guanine nucleobase is shown in the boxes."
}